Biologic and clinical relevance of cytogenetic analysis in primary myelodysplastic syndromes

Cytogenetic abnormalities in myelodysplastic syndromes (MDS) are complex and heterogeneous. The most frequent rearrangements (gains or losses of genetic material) vary from patient to patient, and within the same patient. The prognostic value of these rearrangements has been extensively studied. They allowed the definition of a risk based classification system for MDS (the International Scoring System for evaluating Prognosis, IPSS), proven to be a highly useful method for evaluating prognosis in MDS patients. Despite recent progress in mapping and definition of minimally deleted chromosomal regions, the primary critical genetic events remain to be determined. The recurrent cytogenefic abnormalities associated with MDS are likely to be secondary events contributing to but not initiating the neoplastic phenotype of the disease. (C) 2003 Editions scientifiques et medicales Elsevier SAS. Tous droits reserves.